The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin.
Sandra I BrilAbrahim Al-MamganiNajiba ChargiPeter RemeijerLot A DevrieseJan Paul de BoerRemco de BreePublished in: Head & neck (2021)
Pre-treatment low SMM is associated with CDLT in LA-HNSCC patients treated with primary CRT. Routine SMM assessment may allow for CDLT risk assessment and treatment optimization.